Optimizing dosage of ketamine and xylazine in murine echocardiography

Clinical and Experimental Pharmacology and Physiology

Volumn 34, Issue 5-6, 2007, Pages 499-507

  Xu, Qi ^a,b   Ming, Ziqiu ^a   Dart, Anthony M ^a   Du, Xiao Jun ^a  

^a ALFRED HOSPITAL   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Cardiac function; Echocardiography; Ketamine; Mice; Xylazine

Indexed keywords

KETAMINE; XYLAZINE;

ANESTHESIA; ANESTHESIA INDUCTION; ANIMAL EXPERIMENT; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ANTAGONISM; ECHOCARDIOGRAPHY; HEART FUNCTION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE HYPERTROPHY; HEART RATE; HEART VENTRICLE OVERLOAD; MONOTHERAPY; MOUSE; NONHUMAN;

ADJUVANTS, ANESTHESIA; ADRENERGIC ALPHA-AGONISTS; ANESTHESIA RECOVERY PERIOD; ANESTHESIA, GENERAL; ANESTHETICS, DISSOCIATIVE; ANIMALS; ATROPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; ECHOCARDIOGRAPHY; HEART; HEART RATE; KETAMINE; MALE; MICE; MICE, INBRED C57BL; TIME FACTORS; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING; XYLAZINE;

EID: 33947709581     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2007.04601.x     Document Type: Article

References (44)

1. How OJ, Aasum E, Kunnathu S, Severson DL, Myhre ES, Larsen TS. Influence of substrate supply on cardiac efficiency, as measured by pressure-volume analysis in ex vivo mouse hearts. Am. J. Physiol. Heart Circ. Physiol. 2005; 288: H2979-85.
2. Nahrendorf M, Hu K, Frantz S et al. Factor XIII deficiency causes cardiac rupture, impairs wound healing, and aggravates cardiac remodeling in mice with myocardial infarction. Circulation 2006; 113: 1196-202.
3. Nahrendorf M, Streif JU, Hiller KH et al. Multimodal functional cardiac MRI in creatine kinase-deficient mice reveals subtle abnormalities in myocardial perfusion and mechanics. Am. J. Physiol. Heart Circ. Physiol. 2006; 290: H2516-21.
4. Segers P, Georgakopoulos D, Afanasyeva M et al. Conductance catheter-based assessment of arterial input impedance, arterial function, and ventricular-vascular interaction in mice. Am. J. Physiol. Heart Circ. Physiol. 2005; 288: H1157-64.
5. 2-adrenergic receptor overexpression. Endocrinology 2003; 144: 4097-105.
6. Gao XM, Kiriazis H, Moore XL et al. Regression of pressure overloadinduced left ventricular hypertrophy in mice. Am. J. Physiol. Heart Circ. Physiol. 2005; 288: H2702-7.
7. Tan TP, Gao XM, Krawczyszyn M et al. Assessment of cardiac function by echocardiography in conscious and anesthetized mice: Importance of the autonomic nervous system and disease state. J. Cardiovasc. Pharmacol. 2003; 42: 182-90.
8. Zhang R, Khoo MS, Wu Y et al. Calmodulin kinase II inhibition protects against structural heart disease. Nat. Med. 2005; 11: 409-17.
9. Park SW, Lee SY, Park SJ, Lee SC, Gwon HC, Kim DK. Quantitative assessment of infarct size in vivo by myocardial contrast echocardiography in a murine acute myocardial infarction model. Int. J. Cardiol. 2004; 97: 393-8.
10. Tanaka N, Dalton N, Mao L et al. Transthoracic echocardiography in models of cardiac disease in the mouse. Circulation 1996; 94: 1109-17.
11. Youn HJ, Rokosh G, Lester SJ, Simpson P, Schiller NB, Foster E. Two-dimensional echocardiography with a 15-MHz transducer is a promising alternative for in vivo measurement of left ventricular mass in mice. J. Am. Soc. Echocardiogr. 1999; 12: 70-5.
12. Scherrer-Crosbie M, Steudel W, Hunziker PR et al. Determination of right ventricular structure and function in normoxic and hypoxic mice: A transesophageal echocardiographic study. Circulation 1998; 98: 1015-21.
13. Denvir MA, Sharif I, Anderson T, Webb DJ, Gray GA, McDicken WN. Influence of scanning frequency and ultrasonic contrast agent on reproducibility of left ventricular measurements in the mouse. J. Am. Soc. Echocardiogr. 2005; 18: 155-62.
14. Mor-Avi V, Korcarz C, Fentzke RC, Lin H, Leiden JM, Lang RM. Quantitative evaluation of left ventricular function in a transgenic mouse model of dilated cardiomyopathy with 2-dimensional contrast echocardiography. J. Am. Soc. Echocardiogr. 1999; 12: 209-14.
15. Roth DM, Swaney JS, Dalton ND, Gilpin EA, Ross Jr J. Impact of anesthesia on cardiac function during echocardiography in mice. Am. J. Physiol. Heart Circ. Physiol. 2002; 282: H2134-40.
16. Hart CY, Burnett Jr JC, Redfield MM. Effects of avertin versus xylazine-ketamine anesthesia on cardiac function in normal mice. Am. J. Physiol. Heart Circ. Physiol. 2001; 281: H1938-45.
17. Matsui T, Li L, Wu JC et al. Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J. Biol. Chem. 2002; 277: 22 896-901.
18. Engberding N, Spiekermann S, Schaefer A et al. Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: A new action for an old drug? Circulation 2004; 110: 2175-9.
19. Ichinose F, Bloch KD, Wu JC et al. Pressure overload-induced LV hypertrophy and dysfunction in mice are exacerbated by congenital NOS3 deficiency. Am. J. Physiol. Heart Circ. Physiol. 2004; 286: H1070-5.
20. Kawahara Y, Tanonaka K, Daicho T et al. Preferable anesthetic conditions for echocardiographic determination of murine cardiac function. J. Pharmacol. Sci. 2005; 99: 95-104.
21. Hartley CJ, Michael LH, Entman ML. Noninvasive measurement of ascending aortic blood velocity in mice. Am. J. Physiol. 1995; 268: H499-505.
22. Yang XP, Liu YH, Rhaleb NE, Kurihara N, Kim HE, Carretero OA. Echocardiographic assessment of cardiac function in conscious and anesthetized mice. Am. J. Physiol. 1999; 277: H1967-74.
23. Finsen AV, Christensen G, Sjaastad I. Echocardiographic parameters discriminating myocardial infarction with pulmonary congestion from myocardial infarction without congestion in the mouse. J. Appl. Physiol. 2005; 98: 680-9.
24. Luo J, McMullen JR, Sobkiw CL et al. Class IA phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy. Mol. Cell. Biol. 2005; 25: 9491-502.
25. McMullen JR, Shioi T, Zhang L et al. Deletion of ribosomal S6 kinases does not attenuate pathological, physiological, or insulin-like growth factor 1 receptor-phosphoinositide 3-kinase-induced cardiac hypertrophy. Mol. Cell. Biol. 2004; 24: 6231-40.
26. Dawson D, Lygate CA, Saunders J et al. Quantitative 3-dimensional echocardiography for accurate and rapid cardiac phenotype characterization in mice. Circulation 2004; 110: 1632-7.
27. Collins KA, Korcarz CE, Lang RM. Use of echocardiography for the phenotypic assessment of genetically altered mice. Physiol. Genomics 2003; 13: 227-39.
28. Doursout MF, Chelly JE. Effects of basal anaesthesia on cardiac function. Br. J. Anaesth. 1988; 60 (Suppl.): S119-22 (Review).
29. Manders WT, Vatner SF. Effects of sodium pentobarbital anesthesia on left ventricular function and distribution of cardiac output in dogs, with particular reference to the mechanism for tachycardia. Circ. Res. 1976; 39: 512-17.
30. 2-adrenergic receptor overexpression exacerbates development of heart failure after aortic stenosis. Circulation 2000; 101: 71-7.
31. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-83.
32. Erhardt W, Hebestedt A, Aschenbrenner G, Pichotka B, Blumel G. A comparative study with various anesthetics in mice (pentobarbitone, ketamine-xylazine, carfentanyl-etomidate). Res. Exp. Med. (Berl.) 1984; 184: 159-69.
33. Nielsen GD. Influence of various anaesthetics on the cardiovascular responses to noradrenaline in rats before and after guanethidine. Acta Pharmacol. Toxicol. (Copenh.) 1977; 40: 75-86.
34. Navarro JA, Friedman JR. A clinical evaluation of xylazine and ketamine HCL for cesarean section in the dog. Vet. Med. Small Anim. Clin. 1975; 70: 1075-9.
35. Erdemir H, Huber FC, Corssen G. Dissociative anesthesia with ketamine: A suitable adjunct to epidural anesthesia. Anesth. Analg. 1970; 49: 623-7.
36. Dundee JW, Knox JW, Black GW et al. Ketamine as an induction agent in anaesthetics. Lancet 1970; 1: 1370-1.
37. Lotfy AO, Amir-Jahed AK, Moarefi P. Anesthesia with ketamine. Indications, advantages, and shortcomings. Anesth. Analg. 1970; 49: 969-74.
38. Thorsen T, Gran L. Ketamine/diazepam infusion anaesthesia with special attention to the effect on cerebrospinal fluid pressure and arterial blood pressure. Acta Anaesthesiol. Scand. 1980; 24: 1- 4.
39. Pedersen T. Ketamine as continuous intravenous infusion combined with diazepam in non-abdominal surgery. A randomized double-blind study. Anaesthesist 1981; 30: 111-14.
40. Yamamura T, Kimura T, Furukawa K. Effects of halothane, thiamylal, and ketamine on central sympathetic and vagal tone. Anesth. Analg. 1983; 62: 129-34.
41. Kitagawa H, Yamazaki T, Akiyama T, Mori H, Sunagawa K. Effects of ketamine on in vivo cardiac sympathetic nerve endings. J. Cardiovasc. Pharmacol. 2001; 38 (Suppl. 1): S39-42.
42. Rose'Meyer CM, Rechtman MP, Boura AL, King RG. Presynaptic alpha 2-adrenoreceptors affecting terminal synaptic transmission by the nervi cardiaci accelerantes in the rat. J. Auton. Pharmacol. 1989; 9: 119-27.
43. Georgakopoulos D, Kass D. Minimal force-frequency modulation of inotropy and relaxation of in situ murine heart. J. Physiol. 2001; 534: 535-45.
44. Gueugniaud PY, Vaudelin G, Bertin-Maghit M, Bouchard C, Stagni R, Petit P. Comparison of the myocardial effects of desflurane and isoflurane in healthy patients: Assessment by continuous oesophageal aortic blood flow echo-Doppler. Br. J. Anaesth. 1998; 81: 844-9.